Erythropoietin Levels and Pancreatic Cancer Prognosis
Author Information
Author(s): Welsch Thilo, Zschäbitz Stefanie, Becker Verena, Giese Thomas, Bergmann Frank, Hinz Ulf, Keleg Shereen, Heller Anette, Sipos Bence, Klingmüller Ursula, Büchler Markus W., Werner Jens, Giese Nathalia A.
Primary Institution: University Hospital Heidelberg, Heidelberg, Germany
Hypothesis
The level of endogenous Epo might be a risk factor for PDAC progression in both anemic and non-anemic patients.
Conclusion
Higher sEPO levels counteract anemia but worsen outcomes in PDAC patients.
Supporting Evidence
- Median preoperative hemoglobin levels were reduced by 15% in both chronic pancreatitis and PDAC patients.
- 95% of serum EPO values lay within the normal range.
- Lower serum EPO values were prominent in non-metastatic patients.
- Higher serum EPO levels were an independent prognostic factor for shorter survival.
Takeaway
This study found that high levels of a protein called EPO in the blood can make pancreatic cancer worse, even if patients aren't anemic.
Methodology
The study analyzed hemoglobin, serum Epo, and tissue expression of Epo/Epo receptor in patients with PDAC and chronic pancreatitis.
Potential Biases
Potential biases may arise from the observational nature of the study and the specific patient population.
Limitations
The study primarily focused on a single type of cancer and may not be generalizable to other cancers.
Participant Demographics
Patients included 150 with pancreatic ductal adenocarcinoma and 42 with chronic pancreatitis.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI: 0.80–0.91
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website